Podcast Episodes
Back to Search
Pharmaceutical Executive Daily: White House Withdraws FDA Nomination For Dr. Heidi Overton’s
White House withdraws Dr. Heidi Overton’s FDA commissioner nomination amid Senate GOP pushback, Pfizer and Verismo advance in vivo CAR-T manufacturin…
an hour ago
Pharmaceutical Executive Daily: FDA Approves Cosentyx and Wilserdly
Gilead signs royalty-free licensing deals to broaden Ebola antiviral access, FDA approves Cosentyx for polymyalgia rheumatica and Wilserdly for ESR1-…
1 day ago
Pharmaceutical Executive Daily: FDA Approves Three New Therapies
FDA approves three new therapies, a wave of dealmaking led by Johnson & Johnson, Eli Lilly, AmyriAD Therapeutics, and Sanofi, and Ossium Health’s Kev…
2 days, 1 hour ago
The Ron Lanton Report: Ossium Health's Bone Marrow Bank
Ossium Health’s Kevin Caldwell joins The Ron Lanton Report to explain how banked, deceased-donor marrow is replacing a months-long search for a livin…
2 days, 10 hours ago
Pharmaceutical Executive Daily: FDA Shelves CNPV Program
FDA reportedly shelves its Commissioner’s National Priority Voucher program, Eli Lilly breaks ground on a $3.5 billion Pennsylvania manufacturing sit…
5 days, 3 hours ago
Pharmaceutical Executive Daily: Moderna Outlines Growth Plan at 2026 Analyst Day
Moderna lays out an oncology-driven growth plan at its 2026 Analyst Day, Pfizer and Blackstone sign a co-funding deal worth up to $1.5 billion for be…
6 days, 1 hour ago
Pharmaceutical Executive Daily: FDA Approves Pimjetmi
FDA approves Merck KGaA’s Pimjetmi for tenosynovial giant cell tumor, Parexel’s Stacy Hurt on when patient input should enter the clinical research p…
1 week ago
Pharmaceutical Executive Daily: FDA Requires Safety Label Update on GLP-1 Receptor Agonist
FDA approves Bayer’s asundexian as the first Factor XIa inhibitor for secondary stroke prevention, the FDA requires a new safety label warning across…
1 week, 1 day ago
Pharmaceutical Executive Daily: argenx Acquires Unnatural Products Inc.
argenx acquires Unnatural Products for up to $1.15 billion to expand its immunology capabilities, GiftHealth’s Chip Parkinson on how single-partner p…
1 week, 2 days ago
Pharmaceutical Executive Daily: FDA Grants Accelerated Approval to Rybrevant Faspro
Hims & Hers partners with Eli Lilly to sell Zepbound and Foundayo directly on its platform, Novo Nordisk terminates its research collaboration with K…
1 week, 5 days ago